PMEF
GLUE icon

Point72 Middle East FZE’s Monte Rosa Therapeutics GLUE Stock Holding History

Point72 Middle East FZE’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-9,290
Closed -$52.5K – 545
2023
Q4 		$52.5K Buy
+9,290
New +$36.4K ﹤0.01% 1280

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Point72 Middle East FZE's GLUE Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Monte Rosa Therapeutics (GLUE) in Q1 2024, closing a stake of 9,290 shares — an estimated $52.5K sold.

Point72 Middle East FZE first reported a position in GLUE in Q4 2023 and held it in 1 quarter. The position peaked at $52.5K in Q4 2023. 68 funds tracked by Wall St. Rank hold GLUE as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Monte Rosa Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 9,290 Monte Rosa Therapeutics shares in Q1 2024, an estimated $52.5K.
  • Point72 Middle East FZE first reported a position in Monte Rosa Therapeutics in Q4 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Monte Rosa Therapeutics position peaked at $52.5K in Q4 2023.
  • 68 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.